Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 165Breast Neoplasms 163Carcinoma, Non-Small-Cell Lung 143Colorectal Neoplasms 101Prostatic Neoplasms 99Lung Neoplasms 86Ovarian Neoplasms 78Neoplasm Metastasis 72Multiple Myeloma 71Pancreatic Neoplasms 67Leukemia, Myeloid, Acute 59Endometrial Neoplasms 47Squamous Cell Carcinoma of Head and Neck 44Lymphoma 42Stomach Neoplasms 41Recurrence 40Melanoma 39Glioblastoma 39Carcinoma, Renal Cell 39Brain Neoplasms 39Carcinoma, Hepatocellular 38Urinary Bladder Neoplasms 37Precursor Cell Lymphoblastic Leukemia-Lymphoma 37Lymphoma, Non-Hodgkin 34Leukemia, Lymphocytic, Chronic, B-Cell 34Hematologic Neoplasms 34Glioma 34Sarcoma 33Esophageal Neoplasms 31Small Cell Lung Carcinoma 30

Interventions

defactinib 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Advanced Colorectal Cancer × 30 days × Clear all
NCT06369259 2026-05-20

Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
33 enrolled
Gastrointestinal

Advanced Colorectal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡